Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2010

Mar 30, 2010

33651_dirs_2010-03-30_8fe3c516-481f-463d-b639-380de4ac89ef.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-03-26

Reporting Person: Hillsberg Sanford (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2010-03-26 Common Stock S 25000 $5.66 Disposed 6000 Direct